Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8WWZ3
UPID:
EDAD_HUMAN
Alternative names:
EDAR-associated death domain protein; Protein crinkled homolog
Alternative UPACC:
Q8WWZ3; A2VCK5; A8K7B5; B1AL54; B9ZVW5; Q5VYJ7
Background:
The Ectodysplasin-A receptor-associated adapter protein, also known as EDAR-associated death domain protein or Protein crinkled homolog, plays a pivotal role in the morphogenesis of ectodermal organs. It functions as an adapter protein that interacts with the EDAR DEATH domain, facilitating the coupling of the receptor to the EDA signaling pathway, which is crucial for the activation of NF-kappa-B.
Therapeutic significance:
Linked to ectodermal dysplasia 11A and 11B, conditions characterized by abnormal development of ectodermal structures, this protein's understanding could pave the way for innovative treatments targeting these genetic disorders.